Physician profile
Lauren Bennett
NPI 1245996081
$1,322.74
in general payments reported to CMS, 2019-2025
18 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $83.06 · 2023: $437 · 2024: $475 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.73 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $240.63 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $194.63 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $160.42 | 2023-2024 | Farxiga, Breztri |
| Galderma Laboratories, L.P. | $157.76 | 2025 | Nemluvio |
| Boston Scientific Corporation | $107.98 | 2024-2025 | Embold Fibered |
| Astellas Pharma US INC | $84.93 | 2023-2024 | Veozah |
| Novo Nordisk INC | $54.79 | 2023-2024 | Wegovy |
| Amneal Pharmaceuticals LLC | $50.04 | 2023-2024 | Unithroid |
| Mylan Specialty L.P. | $48.52 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $41.76 | 2024-2025 | Capvaxive |
| Janssen Pharmaceuticals, INC | $34.97 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $33.01 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Daiichi Sankyo INC. | $28.97 | 2022 | |
| Depuy Synthes Sales INC. | $22.01 | 2022 | |
| Shield Therapeutics INC | $16.71 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.05 | 2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.83 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.73 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.